Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)

NCT00363857 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00363857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00363857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2003
Completion date
May 31, 2004
Enrollment
360 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome, restless legs syndrome (rls)